First Time Loading...

Ikena Oncology Inc
NASDAQ:IKNA

Watchlist Manager
Ikena Oncology Inc Logo
Ikena Oncology Inc
NASDAQ:IKNA
Watchlist
Price: 1.32 USD Market Closed
Updated: May 4, 2024

Ikena Oncology Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ikena Oncology Inc
Operating Income Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Ikena Oncology Inc
NASDAQ:IKNA
Operating Income
-$75.4m
CAGR 3-Years
-19%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Operating Income
$24.3B
CAGR 3-Years
4%
CAGR 5-Years
4%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$10.5B
CAGR 3-Years
14%
CAGR 5-Years
6%
CAGR 10-Years
12%
Pfizer Inc
NYSE:PFE
Operating Income
$10.6B
CAGR 3-Years
-6%
CAGR 5-Years
11%
CAGR 10-Years
-5%
Merck & Co Inc
NYSE:MRK
Operating Income
$6.6B
CAGR 3-Years
-10%
CAGR 5-Years
-11%
CAGR 10-Years
-2%
Eli Lilly and Co
NYSE:LLY
Operating Income
$11.3B
CAGR 3-Years
19%
CAGR 5-Years
15%
CAGR 10-Years
9%

See Also

What is Ikena Oncology Inc's Operating Income?
Operating Income
-75.4m USD

Based on the financial report for Dec 31, 2023, Ikena Oncology Inc's Operating Income amounts to -75.4m USD.

What is Ikena Oncology Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-13%

Over the last year, the Operating Income growth was -6%. The average annual Operating Income growth rates for Ikena Oncology Inc have been -19% over the past three years , -13% over the past five years .